The takeaway
Cellebrite DI shows a pronounced seasonal pattern over 6 years of data — strongest in December (+2.8%) and softest in September (−5.9%).
Right now
In July, the stock has risen 40% of years, averaging +1.2%, roughly 1.0 pts behind the S&P 500.
The full picture
Cellebrite DI's most dependable month has been December, higher in 5 of 6 years; September has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | — | — | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in August (+9.5 pts); it has trailed the market most in April (−6.9 pts).
“vs S&P” is Cellebrite DI’s average for a month minus the S&P 500’s average for that same month — isolating Cellebrite DI’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, December has closed higher 80% of the time versus 83% across the last 6 years — the pattern is holding.
Figures are the typical (median) December return and how often it rose — the last 5 years versus the last 6(the heatmap’s default window). This verdict stays anchored to that 6-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: December, up in 5 of 6 Decembers while the other eleven tend to blur together.
Its average (+2.8%) and median (+4.0%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. It is also the calendar's calmest month, its returns swinging least from year to year (a 4.9% spread). Crucially, the gain is the stock's own rather than a rising tide's: December has cleared the S&P 500 by +1.8 points above the index. That consistency sets it apart from the field, where the average stock manages December only about 58% of the time.
The strength clusters rather than stands alone — October–February forms a firm stretch that carries much of the year. The weaker half of the year is plainer: September has been the soft spot — the weakest of 4 months that average a loss (−5.9%), and the edge isn't year-round — the stock has trailed the S&P 500 in April, September, and May. Its roughest month on record was a −30.6% November in 2021 — a reminder of how hard even a seasonal name can fall.
Reassuringly, the tendency has held its shape: the recent five years still track the years behind them.
The takeaway is less about when to buy than what to expect: December aside, the stock's months offer little reliable tilt. With a short 6-year record, the signal is best held loosely.
Short answers on the stock's best month (December), its worst (September), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2020 its best month (December, +2.8%) has run well ahead of its worst (September, −5.9%) — the heatmap above shows how steady that gap has been year to year.
December has been the strongest, averaging +2.8% and closing higher in 5 of 6 years since 2020.
It's the weakest, averaging −5.9% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade